Einzeltreffer — DigiBib

The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

Titel:	COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS
Autor/in / Beteiligte Person:	DESAI, Neil P. ; Soon-Shiong, Patrick ; Trieu, Vuong
Link:	Zum Volltext
Veröffentlichung:	2012
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20120283205 Publication Date: November 8, 2012 Appl. No: 13/368250 Application Filed: February 07, 2012 Claim: 1. (canceled) Claim: 2. A method for enhancing transport of a pharmaceutical agent to the site of an infirmity, which method comprises administering to a human a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin, and wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 18:1 or less. Claim: 3-5. (canceled) Claim: 6. The method of claim 2, wherein the pharmaceutical composition is a liquid and comprises from about 0.1% to about 25% by weight of albumin. Claim: 7. The method of claim 6, wherein the pharmaceutical composition comprises about 0.5% to about 5% by weight of albumin. Claim: 8-9. (canceled) Claim: 10. The method of claim 2, wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less. Claim: 11. The method of claim 2, wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less. Claim: 12. The method of claim 2, wherein the pharmaceutical composition is administered to the human via intravenous administration, intra-arterial administration, intrapulmonary administration, oral administration, inhalation, intra-tracheal administration, intravesicular administration, intramuscular administration, subcutaneous administration, intraocular administration, intrathecal administration, or transdermal administration. Claim: 13-23. (canceled) Claim: 24. A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises albumin in an amount effective to increase transport of the drug to the site of infirmity in a human, or in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the ratio of albumin to pharmaceutical agent is about 18:1 or less. Claim: 25. The pharmaceutical composition of claim 24, wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less. Claim: 26. The pharmaceutical composition of claim 24, wherein the ratio of albumin to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less. Claim: 27. The pharmaceutical composition of claim 24, wherein the infirmity is selected from the group consisting of cancer, arthritis, and cardiovascular disease. Claim: 28-34. (canceled) Claim: 35. A pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a protein in an amount effective to reduce one or more side effects of administration of the pharmaceutical composition into a human, and wherein the ratio of protein to pharmaceutical agent is about 18:1 or less. Claim: 36. The pharmaceutical composition of claim 35, wherein the ratio of protein to pharmaceutical agent in the pharmaceutical composition is about 12:1 or less. Claim: 37. The pharmaceutical composition of claim 35, wherein the ratio of protein to pharmaceutical agent in the pharmaceutical composition is about 9:1 or less. Current U.S. Class: 514/31 Current International Class: 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS